Ixazomib (NINLARO®) capsules ( DrugBank: Ixazomib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03783416 (ClinicalTrials.gov) | June 1, 2019 | 10/12/2018 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial. | Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules | Queen Mary University of London | Takeda Pharmaceuticals International, Inc. | Not yet recruiting | 18 Years | 65 Years | All | 72 | Phase 1 | United Kingdom |